In vitro activity of moxifloxacin compared to other fluoroquinolones against different erythromycin-resistant phenotypes of group A β-hemolytic Streptococcus

被引：6

作者：

Esposito, S

Noviello, S

Ianniello, F

Novelli, A

机构：

[1] Osped Gesu & Maria, Clin Malattie Infett, I-80135 Naples, Italy

[2] Univ Florence, Dipartimento Farmacol, I-50121 Florence, Italy

来源：

CHEMOTHERAPY | 2000年 / 46卷 / 01期

关键词：

group A beta-hemolytic Streptococcus; moxifloxacin; in vitro activity; macrolide-resistance;

D O I：

10.1159/000007252

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The aim of the present study was to evaluate the in vitro activity of moxifloxacin (BAY 12-8039) compared to ciprofloxacin, ofloxacin and sparfloxacin against 156 group A beta-hemolytic Streptococcus strains. Sixty strains were macrolide-, lincosamide- and streptogramin-B-susceptible; 16 strains exhibited a constitutive resistance phenotype; 32 strains exhibited an inducible phenotype, and 48 strains were characterized by the M-type efflux-dependent phenotype, The minimum inhibition concentrations were determined by an agar dilution method according to NCCLS-approved guidelines. Moxifloxacin showed an enhanced activity compared with the other fluoroquinolones against the different macrolide-resistant phenotypes. Copyright (C) 2000 S. Karger AG, Basel.

引用

页码：23 / 27

页数：5

共 25 条

[1]

CAMPORESE A, 1996, INFEZIONI MED, V2, P74

[2]

CIPRIANI P, 1995, MICROBIOL MED, V10, P171

[3]

CRISTIANO L, 1996, MICROBIOL MED, V11, P30

[4] PREVENTION OF RHEUMATIC-FEVER - A STATEMENT FOR HEALTH-PROFESSIONALS BY THE COMMITTEE ON RHEUMATIC-FEVER, ENDOCARDITIS, AND KAWASAKI DISEASE OF THE COUNCIL ON CARDIOVASCULAR-DISEASE IN THE YOUNG, THE AMERICAN HEART ASSOCIATION [J].